1	Analysis of the ARTIC V4 and V4.1 SARS-CoV-2 primers and their impact on the
2	detection of Omicron BA.1 and BA.2 lineage defining mutations
3	
4	Fatima R. Ulhuq <sup>1</sup> *, Madhuri Barge <sup>1</sup> , Kerry Falconer <sup>1</sup> , Jonathan Wild <sup>1</sup> , Goncalo Fernandes <sup>1</sup> ,
5	Abbie Gallagher <sup>1</sup> , Suzie McGinley <sup>1</sup> , Ahmad Sugadol <sup>1</sup> , Muhammad Tariq <sup>1</sup> , Daniel Maloney <sup>1,2</sup> ,
6	Juliet Kenicer <sup>1</sup> , Rebecca Dewar <sup>1</sup> , Kate Templeton <sup>1</sup> , Martin McHugh <sup>1,3*</sup>
7	
8	<sup>1</sup> Viral Genotyping Reference Laboratory, Royal Infirmary of Edinburgh, NHS Lothian, EH16
9	4SA, Edinburgh, United Kingdom.
10	<sup>2</sup> Institute of Evolutionary Biology, University of Edinburgh, EH9 3JR, Edinburgh, United
11	Kingdom
12	<sup>3</sup> School of Medicine, University of St Andrews, KY16 9TF, St Andrews, United Kingdom
13 14	*To whom correspondence should be addressed.
15	e-mail: fatima.ulhuq@nhslothian.scot.nhs.uk, mpm20@st-andrews.ac.uk
16	
17	Abstract
18	The ARTIC protocol uses a multiplexed PCR approach with two primer pools tiling the entire
19	SARS-CoV-2 genome. Primer pool updates are necessary for accurate amplicon
20	sequencing of evolving SARS-CoV-2 variants with novel mutations. The suitability of the
21	ARTIC V4 and updated V4.1 primer scheme was assessed using whole genome sequencing
22	of Omicron from clinical samples using Oxford Nanopore Technology. Analysis of Omicron
23	BA.1 genomes revealed that 93.22% of clinical samples generated improved genome
24	coverage at 50x read depth with V4.1 primers when compared to V4 primers. Additionally,
25	the V4.1 primers improved coverage of BA.1 across amplicons 76 and 88, which resulted in
26	the detection of the variant defining mutations G22898A, A26530G and C26577G. The
27	Omicron BA.2 sub-variant (VUI-22JAN-01) replaced BA.1 as the dominant variant by March
28	2022, and analysis of 168 clinical samples showed reduced coverage across amplicons 15 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 and 75. Upon further interrogation of primer binding sites, a mutation at C4321T (present in 30 163/168, 97% of samples) was identified as a possible cause of complete dropout of 31 amplicon 15. Furthermore, two mutations were identified within the primer binding regions for 32 amplicon 75: A22786C (present in 90% of samples) and C22792T (present in 12.5% of 33 samples). Together, these mutations may result in reduced coverage of amplicon 75 and 34 further primer updates would allow the identification of the two BA.2 defining mutations 35 present in amplicon 75; A22688G and T22679C. This work highlights the need for ongoing 36 surveillance of primer matches as circulating variants evolve and change.

37

# 38 Keywords

- 39 SARS-CoV-2, Nanopore, Whole Genome Sequencing, Omicron, BA.1, BA.2
- 40

#### 41 Introduction

42

On the 11<sup>th</sup> March 2020, the World Health Organisation (WHO) declared a global pandemic
following the emergence of the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). To date, 5<sup>th</sup> September 2022, there have been over 600 million confirmed cases and
over 6.5 million deaths worldwide [1].

47

Worldwide genomic surveillance of SARS-CoV-2 has been employed to better understand 48 49 the viral mutation rate and transmission dynamics of emerging SARS-CoV-2 variants. 50 Identifying the genetic diversity of circulating SARS-CoV-2 variants aids research into 51 understanding the pathogenicity of variants, identifying sites on the genome that may reduce 52 the effectiveness of vaccines and drug therapies, and ultimately inform the design of future 53 therapeutics [2-8]. Additionally, real-time surveillance of SARS-CoV-2 outbreaks informs the implementation of control and prevention measures for SARS-CoV-2 transmission. As of 6<sup>th</sup> 54 55 September 2022, 12.9 million SARS-CoV-2 genomes have been submitted to the global 56 initiative on sharing all influenza data (GISAID) database (GISAID - gisaid.org).

57

58 The most widely used protocol to sequence SARS-CoV-2 is the ARTIC amplicon-based 59 targeted whole-genome sequencing approach. The ARTIC protocol is a freely available 60 protocol allowing for rapid responses to changes in the SARS-CoV-2 viral genome [9-14]. 61 This is a multiplex PCR approach, which consists of 98 pairs of primers that spans the 62 ~30kb genome. However, one of the major limitations of the amplicon approach is the static 63 nature of the primer scheme as the virus evolves and develops mutations and structural 64 variants, which can lead to primer mismatches and an inability to construct near-complete viral genomes. Since January 2020 the primer scheme has been updated four times in 65 response to changes in the prevailing virus lineages [9-11, 13, 14]. Inability of a given 66 primer to bind to the complementary sequence results in amplicon dropouts and mutations in 67

the Beta, Delta and Gamma variants resulted in less efficient amplification of amplicons 72,
74 and 76 [14, 15].

70

71 The ARTIC V4.1 primers were introduced to improve primer binding and eliminate amplicon 72 dropouts for BA.1. In this work the suitability of the ARTIC V4.1 primer scheme by 73 comparison with the V4 primer scheme will be assessed and reported for the Omicron BA.1 74 lineage. To do this, Nanopore sequencing was used to sequence 70 SARS-CoV-2 samples, 75 with both V4 and V4.1 primers, obtained from RT-PCR confirmed COVID-19 positive 76 patients. Subsequently, BA.2 was assigned as a variant under investigation (VUI-22JAN-01) 77 and has increased in prevalence. The ability of the V4.1 primer scheme to generate near 78 complete genome coverage of BA.2 was also investigated in this work.

# 80 Methods

81 Patient samples and RNA extraction. 344 SARS-CoV-2 positive clinical samples were 82 collected between Dec-2021 and Mar-2022. There were 325 nose and throat swabs 83 (94.48%), 18 throat swabs (5.23%) and 1 tracheal aspirate (0.29%). Samples were 84 confirmed positive for at least two SARS-CoV-2 real-time RT-PCR targets using a range of diagnostic assays in NHS laboratories across the east of Scotland and referred to the Viral 85 86 Sequencing Service, Royal Infirmary of Edinburgh, for sequencing. RNA extraction was 87 performed on confirmed SARS-CoV-2 samples using two automated extraction platforms; the Biomérieux NucliSENS EMAG® and Abbot m2000sp. First, SARS-CoV-2 positive 88 samples were inactivated and lysed using NucliSENS<sup>®</sup> easyMAG<sup>®</sup> Lysis Buffer (Biomérieux, 89 90 ref 280134). When using the m2000sp, VTM and lysis buffer were mixed at a 1:1 ratio and 91 equal volumes of diluted lysis buffer was added to each sample for lysis (500 µl lysis buffer + 500 ul sample). For the Biomérieux NucliSens EMAG<sup>®</sup>, neat lysis buffer was added to each 92 sample (200 µl sample + 2 mL lysis buffer). The procedure was followed as outlined in the 93 94 manufacturer's instructions and the RNA eluted in 110 µl. VTM only was used as an internal 95 control for each extraction run.

96 Ethical approval. This work was performed as a diagnostic lab validation and ethical
97 approval was obtained from the NHS Lothian NRS BioResource and Tissue Governance
98 Unit (reference 10/S1402/33).

99 ARTIC LoCost protocol Nanopore library preparation. ONT libraries for SARS-CoV-2 100 sequencing was performed according to the ARTIC Lo-Cost protocol [11, 12], with both V4 101 and V4.1 primers. Slight modifications to the published method were made during the DNA 102 barcode ligation step. For a single reaction, the ligation mastermix was prepared by adding 103 nuclease-free water (2.1 µl), Ultra II Ligation Mastermix (5.0 µl), Ligation Enhancer (0.2µl) 104 (NEBNext<sup>®</sup> Ultra<sup>™</sup> II Ligation Module, E7595S) and the unique barcode (1.2 µl) (ONT Native 105 Barcoding Expansion 96, EXP-NBD196). The end prep reaction mixture (1.5 µl), from the

previous step, was added to the ligation mastermix (8.50 µl) containing the unique barcodes.

107 The protocol was then followed as outlined in the ARTIC Lo-Cost protocol [11].

108 **Nanopore sequence analysis.** High accuracy basecalling was performed using Guppy 109 (v4.4.0) (Oxford Nanopore Technologies) and demultiplexed using guppy barcoder with the 110 option 'require barcodes both ends' and a minimum score of 60. The downstream analysis was performed using the ARTIC fieldbioinformatics pipeline (v1.2.1) (https://github.com/artic-111 112 network/fieldbioinformatics) and nanopolish variant calling (https://github.com/jts/nanopolish) 113 to generate a consensus sequence for each sample in FASTA format. RAMPART (v1.0.6) 114 (https://github.com/artic-network/rampart) was used to calculate genome coverage at 20x, 115 100x and 200x read depth. Nextclade (https://clades.nextstrain.org) was used to determine 116 the number of SNPs between the reference genome (NC\_045512.2) and sequenced clinical 117 isolates. PANGOLIN (v3.1.20) (https://github.com/cov-lineages/pangolin) [16, 17] was used 118 to assign a lineage to all SARS-CoV-2 samples, using the pangoLEARN algorithm. Aln2type 119 (v0.0.3) (https://github.com/connor-lab/aln2type) (analysis performed on 8th Feb 2022) was 120 used to identify variant defining mutations for variants of concern (VOC) and variants under 121 investigation (VUI) as curated by Public Health England (https://github.com/phe-122 genomics/variant\_definitions).

The metrics and results of all experiments are available in the supplementary data (Datasets 1, 2 and 3). For direct V4 to V4.1 primer comparison, two separate 48-plex libraries were loaded (Run1 and Run2, Dataset 1). For the analysis of BA.1 and BA.2 samples with V4.1 primers only, a total of 7, 48-plex libraries were loaded and sequenced.

Sequence alignment. Sequences were aligned to the reference SARS\_CoV-2 isolate NC\_045512.2 using MAFFT (v7.505) (https://anaconda.org/bioconda/mafft) [18] and visualised using Jalview2 (v2.11.2.2) [19]. Depth at each nucleotide position was extracted using SAMtools (v1.15) (https://github.com/samtools/samtools).

131 Quality Control. Samples were run as 48-plex libraries, each included a negative and 132 positive control (SARS-CoV-2 B.1 lineage, collected June 2020), and two extraction negative 133 controls (Datasets 1, 2 and 3). For all sequencing runs, the negative control and extraction 134 negative controls generated <5 mapped reads and 0% genome coverage at 20x. The viral 135 lysate of the positive control generated 99.90% genome coverage at 20x read depth. All 136 seven expected mutations were detected for the positive control and assigned the PANGO 137 lineage B.1. Clinical samples that generated <70% whole genome coverage were excluded 138 from further analysis.

Data availability statement. The data have been deposited with links to BioProject
accession number PRJNA902683 in the NCBI BioProject database
(http://www.ncbi.nlm.nih.gov/bioproject/902683).

142 **Conflict of interest statement.** The authors have declared no conflict of interest.

143

144 **Results** 

145

# 146 Genome coverage of Omicron BA.1 with ARTIC V4 and V4.1 primers

147 In total, nine (13%) clinical samples were identified as Delta (VUI-210CT-01 or VOC-148 21APR-02), 59 (84%) clinical samples were identified as Omicron lineage BA.1 (VOC-149 21NOV-01) and two (3%) clinical samples were identified as Omicron BA.2 (VUI-22JAN-01) 150 with ARTIC V4 and V4.1 primers (Dataset 1). For the Delta lineage samples, the median 151 genome coverage at 20x read depth improved from 99.40% with V4 primers to 99.90% with 152 V4.1 primers, respectively. All nine samples were confirmed as either VUI-21OCT-01 or 153 VOC-21APR-02 with both V4 and V4.1 primers. The two Omicron BA.2 samples increased 154 from 95.20% to 99.30% and 97.20% to 99.90% genome coverage, with V4 and V4.1 155 primers, respectively. Both samples had probable aln2type VUI-22JAN-01 calls with V4 156 primers, however one sample improved from probable to confirmed with V4.1 primers.

157

Initial in-depth analysis focussed on Omicron BA.1, as the increasingly dominant variant and the main component of the runs during sequencing. The genome coverage at >50x read depth was investigated to identify regions of the genome with reduced amplification. Nucleotide positions that generated <50x read depth in 15% or more of the samples were considered as low coverage regions. Coverage was compared between the V4 and V4.1 primer scheme. The V4.1 primer scheme included a new batch of primers added to the V4 primers to improve the coverage across amplicons 10, 23, 27, 76, 79, 88, 89 and 90 [13].

165

166 Use of the V4 primers generated reduced amplification of nucleotides across 18 different 167 amplicons, with less than 50x read depth in more than 15% of sequenced samples (Figure 168 1A, Table S1). The use of the V4 primers resulted in dropout of amplicons 76 and 90 169 (Figures 1A and 2A, Table S1) and poor coverage across amplicons 10, 23, 79, 88 and 89 170 (Figures 1A and 2A, Table S1). Reduced coverage of these amplicons was due to primer 171 mismatches between the V4 primer scheme and the SARS-CoV-2 BA.1 sequence. Reduced 172 coverage of nucleotide positions across amplicons 22, 37, 72, 73, 74 and 95 were due to 173 small deletions within the genome (3-9bp) (Table S1). Reduced amplification of amplicons 174 21, 29, 31, 51 and 60 (Figure 1A, Table S1) were detected with the V4 primers in samples 175 that generated <60,000 mapped reads. Due to the low number of mapped reads for these 176 samples, the reduced coverage within these amplicons is likely to be due to the quality and 177 quantity of the extracted RNA.

Utilisation of the V4.1 primer scheme [13] resulted in an overall improvement in genome coverage. The addition of the V4.1 alt primers increased the median sequencing depth across all eight amplicons with the modified primers in the updated V4.1 primer scheme (Figure 2A). Strikingly, the additional primers rescued the dropout of amplicons 76 and 90 and increased sequencing coverage across amplicons 10, 23, 78, 88 and 89 (Figure 2A). The number of amplicons with nucleotide positions that generated <50x coverage in 15% or

184 more samples decreased from 18 amplicons with V4, to 10 amplicons with V4.1 primers 185 (Figure 1B, Table S2). Despite the addition of modified primers to better amplify amplicon 186 88, the coverage defect was not completely restored. However, the percentage of 187 sequenced samples <50x coverage within this region decreased, from 40.68 - 66.1% to 188 22.03 - 33.9%, with V4 and V4.1 primers, respectively (Tables S1 and S2). Regions with 189 lower coverage with the V4.1 primers were investigated to identify the root cause of lower 190 read depth at certain nucleotide positions. The reduced coverage across amplicons 22, 37, 191 72, 73, 74 and 95 were due to small deletions within the genome (3-9 bp). Reduced 192 amplification of amplicons 21, 51 and 66 was detected in samples that generated <60,000 193 mapped reads, suggesting overall lower genome quality.

194

Analysis of all BA.1 sequences highlighted that in total, 2668 nucleotides generated reduced 195 196 coverage (<50x read depth in 15% or more samples) with the V4 primers compared to 1085 197 nucleotides with the V4.1 primers (Tables S1 and S2). The median number of reads mapped 198 per sample was 98,609 and 114,476 with V4 and V4.1 primers, respectively (Dataset 1). Additionally, the median number of masked bases (N's) decreased from 1050 N's to 126 N's 199 200 with the V4 and V4.1 primers, respectively (Dataset 1). In addition, the median number of 201 SNPs increased from 52 to 58 with the V4 and V4.1 primers, respectively. This highlights the 202 overall improvement detected with the V4.1 primers when compared to V4. The percentage 203 of samples that generated improved genome coverage with the V4.1 primers when 204 compared to V4 was 93.22% (55/59) at 50x read depth (Figure 2B). Additionally, 37 out of 205 59 (62.71%) samples generated increased number of mapped reads with the V4.1 primers 206 compared to V4 (Dataset 1). The median genome coverage per sample for V4 primers at 207 200x, 100x and 20x was 95.59%, 96.30% and 98.00%, respectively (Dataset 1). The median 208 coverage per genome with V4.1 primers at 200x, 100x and 20x was 98.80%, 99.60%, and 209 99.90%, respectively.

210

211

#### PANGO Lineage and VOC/VUI calls of Omicron BA.1 with ARTIC V4 and V4.1 primers 212

213 PANGOLIN was used to assign a lineage to all SARS-CoV-2 consensus sequences and 214 58/59 samples received identical PANGO lineages, either BA.1 (37/59) or BA.1.1 (21/59) 215 with V4 and V4.1 primers (Dataset 1). The specificity of the lineage call for vssfru 032 216 altered from BA.1 to BA.1.1 with the V4.1 primers (vssfru 032b) when compared to V4 217 (vssfru\_032b) (Dataset 1). Based on PHE variant definitions, aln2type requires the detection 218 of 17 variant defining mutations to be assigned as SARS-CoV-2 BA.1 (VOC-21NOV-01). All 219 17 variant defining mutations must be detected for a 'confirmed' VOC/VUI status call. 220 Interestingly, more accurate VOC-21NOV-01 status calls were obtained in 55/59 samples 221 (93.22%), improving from probable to confirmed VOC-21NOV-01 when using V4.1 222 compared to V4 primers (Dataset 1). The remaining 4/59 samples (6.78%) had probable 223 VOC-21NOC-01 calls with both V4 and V4.1 primers (Dataset 1).

224 Further analysis highlighted that the median number of variant defining mutations detected 225 for VOC-21NOV-01, increased from 14 to 17 with the V4 and V4.1 primers, respectively. The 226 increased coverage across amplicons 76 and 88 with the V4.1 primers (Figure 2A) resulted 227 in increased coverage at position 22898, 26530 and 26577 (Figure 3A) and the detection of 228 the three additional variant defining SNPs, G22898A, A26530G and C26577G, present in 229 amplicons 76 and 88 (Figure 3B). In addition, increased coverage of amplicon 60 allowed 230 the identification of the variant defining mutation A18163G (Figure 3A and 3B). In total, 138 231 variant defining bases were masked (N's) with the V4 primers and this was reduced to 12 232 bases with V4.1 primers (Figure 3B). The 12 masked variant defining bases at position 233 18163 (n=2), 22898 (n=2), 26530 (n=4) and 26577 (n=4) were only detected in 4 BA.1 234 samples (Figure 3B) that generated <30,000 mapped reads, therefore overall reduced 235 genome quality.

236 A larger dataset of 106 positive SAR-CoV-2 BA.1 samples collected between 21-02-2022 237 and 07-03-2022 were investigated to compare the aln2type results obtained from the side-238 by-side V4 and V4.1 comparison above. Comparable results were obtained with reduced 239 coverage at positions 18163, 22898, 26530 and 26577 (present in amplicons 60, 76 and 88) 240 with the V4.1 primers (Figure S1A and S1B). Reduced amplification of these regions 241 contributed to only 16/106 (15.1%) of samples with probable VOC-21NOV-01 calls (Dataset 242 2) and a total of 48 masked variant defining mutations (Figure S1B, Dataset 2). Altogether, 243 these results highlight the overall improvement in the amplification of Omicron BA.1 with the 244 V4.1 primers when compared to V4.

245

# 246 Genome coverage of Omicron BA.2 with ARTIC V4.1 primers

247 Genome coverage of Omicron BA.2 (VUI-22JAN-01) was further assessed with the ARTIC 248 V4.1 primers by analysing 168 SARS-CoV-2 positive BA.2 samples collected from 2022-02-249 21 – 2022-03-06. Overall, the median genome coverage of 168 BA.2 samples with V4.1 250 primers at 200x, 100x and 20x were 96.15%, 98.60% and 99.30%, respectively (Dataset 3). 251 The median number of mapped reads was 82,598 (Dataset 3). The median number of 252 masked bases (N's) was 387 with a median number of 68 SNPs across the BA.2 genomes. 253 In total, 16 amplicons were identified with <50x read depth in more than 15% of the samples 254 sequenced (Figure 4, Table S3). Reduced coverage of nucleotides across amplicons 37, 72, 255 95 and 99 were due to deletions within BA.2 (8-26 bp deletions). It was not possible to 256 identify a cause for the reduced read depth of nucleotides present in amplicons 1, 21, 22, 51, 257 60, 66, 74, 76, 88 or 90, however, BA.2 samples with reduced nucleotide coverage in these 258 regions generated a total of <60,000 mapped reads per genome. This suggests the low 259 coverage may be due to pre-analytical issues with the amount and guality of RNA. Dropout 260 of amplicon 15 and poor coverage across amplicon 75 was detected (Figure 4, Table 3). 261 BA.2 samples with reduced nucleotide coverage within these regions generated >60,000

262 mapped reads. These samples were further investigated to identify the root cause of 263 reduced coverage.

264 With regards to amplicon 15, a SNP (C4321T) was identified in 163/168 samples (97%) (Figure 5A). The primer 'SARS-CoV-2 15 LEFT' binds within this region of the genome and 265 the C4321T SNP sits 9 bp into the forward primer (Figure 5A). In amplicon 75 two SNPs 266 267 were identified within the primer binding region of 'SARS-CoV-2\_75 RIGHT', A22786C and 268 C22792T (Figure 5B). The variant defining mutation, A22786C is present in 90% of samples 269 (151/168) while C22792T is present in 12.5% of samples (21/168). The variant defining 270 mutation, A22786C sits at the end of the 'SARS-CoV-2 75 RIGHT' primer (3' region), 271 therefore does not have a significant impact on primer binding. However, samples with the 272 C22792T SNP exhibit dropouts in amplicon 75, highlighting the importance of this site for 273 primer binding (Figure 5B). Updates to these primers may provide improved coverage of 274 amplicons 15 and 75.

275 Reduced amplification of amplicons 75, 76 and 88 resulted in reduced sequencing coverage 276 of four variant defining SNPs (T22679C, A22688G, A22786C and C26577G) (Figure S2, 277 Table S3) required for aln2type Omicron BA.2 variant under investigation (VUI-22JAN-01) 278 call criteria (Table S3). BA.2 (VUI-22JAN-01) required detection of 20 variant defining 279 mutations for a confirmed status call and 80 probable VUI-22JAN-01 calls were obtained 280 with a total of 197 masked bases (N's) at variant defining positions across all BA.2 samples 281 sequenced (Figure S2B, Dataset 3). Of these, 71 BA.2 samples generated over 90% 282 genome coverage at 20x read depth and were then further investigated. The 71 probable 283 VUI-22JAN-01 samples accumulated a total of 131 masked bases (N's) at the following 284 variant defining positions: 2790 (n=3), 9424 (n=29), 18163 (n=7), 22679 (n=34), 22688 285 (n=34), 22775 (n=5), 22786 (n=9), 26577 (n=10) (Dataset 3). As expected, masked bases 286 (N's) were detected at position 22679, 22688, 22786 and 26577 due to lower coverage 287 across amplicons 75, 76 and 88. However, the number of samples with masked bases at 288 position 9424 (n=29) was unexpected, as 27 out of the 29 samples generated more than 20x

coverage at position 9424 (Table S4). Further analysis revealed that the discrepancy in the detection of A9424G was due to the presence of mixed bases, with variant base calls often having low quality. This resulted in masking of the variant defining SNP A9424G in our consensus calling pipeline due to low support for the variant call.

293 In addition, reference base calls at variant defining sites, at either position 670 (6/168, 4%) 294 or 9866 (1/168, 0.6%) (Table S5) contributed to probable VUI-22JAN-01 calls in seven BA.2 295 samples. This might be due to diversity within the BA.2 population, where reversion 296 mutations may have occurred. Furthermore, a small cluster of 10 BA.2 samples were 297 defined as having mixed calls for the variant defining mutation at position 29510 (Table S5). 298 An alignment comparing vssfru 253 (confirmed A29510C SNP), the SARS-CoV-2 reference 299 genome (NC\_045512.2) and the 10 BA.2 samples with aln2type mixed call status (Figure 300 S3) was generated (Figure S3). The alignment highlights the presence of A29510C within all 301 10 BA.2 samples, however an additional SNP, G29511T was present downstream (Figure 302 S3). The expected codon is CGT, however, a subset of BA.2 samples have CTT within their 303 consensus sequence, this is then defined as a mixed call by aln2type. Strikingly, the 304 presence of this unique mutation, not identified within any other sequences analysed within 305 this work, may indicate transmission during a small outbreak.

306

#### 307 Conclusion

308 In summary, use of the ARTIC V4.1 primers, when compared to V4 primers, improved 309 overall genome coverage of Omicron BA.1. The addition of the alt primers improved the 310 sequencing depth across all eight amplicons which resulted in more accurate PANGO 311 lineage and VOC/VUI calls. Further analysis of the BA.2 sub-variant revealed complete drop-312 out of amplicon 15 and reduced coverage of amplicon 75. Additionally, lower read depth of 313 amplicon 75 resulted in the masking of two variant defining mutations. This work highlights 314 the need for ongoing surveillance of primer matches as circulating variants evolve and 315 change. The use of different primer schemes should be an important consideration when

- 316 identifying and assigning variants of concern and the genome completeness of SARS-CoV-2
- 317 genomes should be routinely monitored with updates to primer schemes when required.
- 318
- 319

### 320 Acknowledgements

We would like to thank diagnostic laboratory teams at NHS Borders, NHS Fife, NHS Grampian, NHS Highland, NHS Lothian, NHS Orkney, NHS Shetland, and NHS Tayside for providing samples used in this work. We are also grateful to colleagues in Public Health Microbiology at Public Health Scotland, NHS Greater Glasgow and Clyde, National Services Division of NHS National Services Scotland, and Scottish Government with whom the sequencing service was established.

# 327 References

328 329	1.	WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int.
330	2	Nadaqu & Baakmann & Tanalaku I. Vaughan T. Hadaraft F. at al Quantifuing SADS
222	Ζ.	Nadeau S, Beckmann C, Topolsky I, Vaugnan T, Hodcroit E, <i>et al.</i> Quantifying SARS-
332		Cov-z spread in Switzenand based on genomic sequencing data. <i>medRxiv</i> 2020.
333 334	3.	Martin J, Klapsa D, Wilton T, Zambon M, Bentley E, et al. Tracking SARS-CoV-2 in
335		Sewage: Evidence of Changes in Virus Variant Predominance during COVID-19
336		Pandemic. Viruses;12.
337	4	Vola E. Michael C. Chand M. Dewett JO. Jakasan D. et al Transmission of CADC CoV
338	4.	Volz E, Misnra S, Chand M, Barrett JC, Johnson R, <i>et al.</i> Transmission of SARS-Cov-
240		2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data.
340 341		mearxiv 2021.
342	5.	Chen C, Nadeau S, Yared M, Voinov P, Xie N, et al. CoV-Spectrum: Analysis of
343		Globally Shared SARS-CoV-2 Data to Identify and Characterize New Variants.
344		Bioinformatics 2021;38:1735–1737.
345	0	
346	6.	Gram MA, Emborg H-D, Schelde AB, Friis NU, Nielsen KF, et al. Vaccine
347 348		Alpha Dolta or Omicrop SARS CoV 2 variant: A pationwide Danich cohort study
340		PLOS Med 19
350		
351	7.	Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, et al. Covid-19 Vaccine
352		Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med 2022;386:1532-
353		1546.
354 355	8.	Kirsebom FCM, Andrews N, Stowe J, Toffa S, Sachdeva R, et al. COVID-19 vaccine
356		effectiveness against the omicron (BA.2) variant in England. Lancet Infect Dis
357		2022;22:931–933.
358 359	9.	Quick J. nCoV-2019 sequencing protocol V.1. protocols.io.
360 361	10.	Quick J. nCoV-2019 sequencing protocol v2 (GunIt) V.2. protocols.io.
362 363	11.	Quick J. nCoV-2019 sequencing protocol v3 (LoCost). protocols.io.
364 365	12	Tyson IR James P. Stoddart D. Snarks N. Wickenbagen A. et al. Improvements to
366	12.	the ARTIC multiplex PCR method for SARS-CoV-2 denome sequencing using
500		and rating manupler i on memorial of onto-ouv-2 genome sequencing using

367 nanopore. *bioRxiv* 2020.

368

372

375

379

383

387

391

- 369 13. ARTIC Network. SARS-CoV-2 V4.1 update for Omicron variant.
   370 https://community.artic.network/t/sars-cov-2-v4-1-update-for-omicron-variant/342
   371 (2021).
- 373 14. ARTIC Network. SARS-CoV-2 version 4 scheme release.
  374 https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312.
- 15. Davis JJ, Long SW, Christensen PA, Olsen RJ, Olson R, *et al.* Analysis of the ARTIC
  Version 3 and Version 4 SARS-CoV-2 Primers and Their Impact on the Detection of
  the G142D Amino Acid Substitution in the Spike Protein. *Microbiol Spectr*,9.
- 380 16. O'Toole Á, Scher E, Underwood A, Jackson B, Hill V, *et al.* Assignment of
   apidemiological lineages in an emerging pandemic using the pangolin tool. *Virus Evol*;7.
- 17. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, *et al.* A dynamic
   nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol* 2020;5:1403–1407.
- 18. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple
  sequence alignment based on fast Fourier transform. *Nucleic Acids Res*2002;30:3059–3066.
- Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview Version 2--a
  multiple sequence alignment editor and analysis workbench. *Bioinformatics*2009;25:1189–1191.
- 395

# **Figure legends**

Figure 1. Coverage profile of SARS-CoV-2 BA.1 using V4 and V4.1 primers. Percentage
of samples with >50x coverage at each nucleotide position for the assembly of 59 SARSCoV-2 BA.1 samples with A. V4 primers (in blue) or B. V4.1 primers (in orange). The depth
of each nucleotide position was generated using SAMtools on the primer trimmed alignment
files.

Figure 2. Increased sequencing depth across amplicons and increased genome
coverage in SARS-CoV-2 BA.1 samples amplified with V4.1 primers. A. Median
coverage across amplicons 10, 23, 27, 76, 79, 88, 89 and 90 with V4 (blue) and V4.1
(orange). B. Percentage genome coverage at >50x coverage of all 59 SARS-CoV-2 BA.1
samples. Assemblies with V4 primers in blue, and V4.1 primers in orange.

Figure 3. Increased sequencing depth at BA.1 variant defining positions 22898, 26530 and 26577. Analysis of 59 BA.1 samples with V4 and V4.1 primers. A. Sequencing depth of variant defining mutations at all 17 nucleotide positions as defined by aln2type for BA.1 with V4 (blue) and V4.1 (orange) primers. B. Number of samples with masked bases (N's) at variant defining nucleotide positions in BA.1 samples with V4 (blue) and V4.1 (orange) primers.

Figure 4. Coverage profile of SARS-CoV-2 BA.2 using V4.1 primers. Percentage of samples with >50x coverage at each nucleotide position for the assembly of 168 SARS-CoV-2 BA.2 samples with V4.1 primers (in green). The depth of each nucleotide position was generated using SAMtools on the primer trimmed alignment files.

Figure 5. Identification of SNPs responsible for low coverage of amplicons 15 and 75
in BA.2 samples. Multiple sequence alignment using MAFFT (v7.505) of NC\_045512.2
reference with selected BA.2 samples with A. reduced coverage of amplicon 15 or B.
reduced coverage of amplicon 75. Alignments viewed using Jalview (v2.11.2.2).

Figure S1. Sequencing coverage and aln2type VOC-21NOV-01 defining mutations.
Analysis of 106 BA.1 samples with V4.1 primers. A. Sequencing depth of variant defining
mutations at all 17 nucleotide positions as defined by aln2type for BA.1. B. Number of
samples with masked bases (N's) at variant defining nucleotide positions in BA.1 samples.

Figure S2. Sequencing coverage and aln2type VUI-22JAN-01 defining mutations.
Analysis of 168 BA.2 samples. A. Sequencing depth of variant defining mutations at all 20

427 nucleotide positions as defined by aln2type for BA.2. B. Number of samples with masked
428 bases (N's) at variant defining nucleotide positions in BA.2 samples.

# 429 Figure S3. A29510C aln2type mixed-call status due to downstream mutation present

430 **in subset of samples.** Multiple sequence alignment using MAFFT (v7.505) of NC\_045512.2

- 431 reference with 10 BA.2 samples with mixed-call status for A29510C variant defining mutation
- 432 and vssfru\_253 (A29510C detected). Alignment viewed using Jalview (v2.11.2.2).

433

#### 434 Supplementary Datasets

Dataset 1. Overview of SARS-COV-2 genome coverage with V4 and V4.1 primers. Total
number of SNPs and masked bases (N's) generated using NextClade. Mapped reads, 20x,
100x and 200x coverage data generated using RAMPART (v1.0.6). Lineage and conflict
generated using PANGOLIN (v3.1.20). PHE-label, status and mutation calls generated using
aln2type (v0.0.3). Data from two 48-plex libraries (Run1 and 2).

Dataset 2. Overview of SARS-COV-2 BA.1 genome coverage with V4.1 primers. Total number of SNPs and masked bases (N's) generated using NextClade. Mapped reads, 20x, 100x and 200x coverage data generated using RAMPART (v1.0.6). Lineage and conflict generated using PANGOLIN (v3.1.20). PHE-label, status and mutation calls generated using aln2type (v0.0.3). Data from seven 48-plex libraries (Run3 – Run9) displaying only the BA.1 samples.

Dataset 3. Overview of SARS-COV-2 BA.2 genome coverage with V4.1 primers. Total number of SNPs and masked bases (N's) generated using NextClade. Mapped reads, 20x, 100x and 200x coverage data generated using RAMPART (v1.0.6). Lineage and conflict generated using PANGOLIN (v3.1.20). PHE-label, status and mutation calls generated using aln2type (v0.0.3). Data from seven 48-plex libraries (Run3 – Run9) displaying only the BA.2 samples.



**Figure 1. Coverage profile of SARS-CoV-2 BA.1 using V4 and V4.1 primers.** Percentage of samples with >50x coverage at each nucleotide position for the assembly of 59 SARS-CoV-2 BA.1 samples with **A.** V4 primers (in blue) or **B.** V4.1 primers (in orange). The depth of each nucleotide position was generated using SAMtools on the primer trimmed alignment files.



**Figure 2.** Increased sequencing depth across amplicons and increased genome coverage in SARS-CoV-2 **BA.1 samples amplified with V4.1 primers. A.** Median coverage across amplicons 10, 23, 27, 76, 79, 88, 89 and 90 with V4 (blue) and V4.1 (orange). **B.** Percentage genome coverage at >50x coverage of all 59 SARS-CoV-2 BA.1 samples. Assemblies with V4 primers in blue, and V4.1 primers in orange.



**Figure 3.** Increased sequencing depth at BA.1 variant defining positions 22898, 26530 and 26577. Analysis of 59 BA.1 samples with V4 and V4.1 primers. **A.** Sequencing depth of variant defining mutations at all 17 nucleotide positions as defined by aln2type for BA.1 with V4 (blue) and V4.1 (orange) primers. **B.** Number of samples with masked bases (N's) at variant defining nucleotide positions in BA.1 samples with V4 (blue) and V4.1 (orange) primers.



**Figure 4. Coverage profile of SARS-CoV-2 BA.2 using V4.1 primers.** Percentage of samples with >50x coverage at each nucleotide position for the assembly of 168 SARS-CoV-2 BA.2 samples with V4.1 primers (in green). The depth of each nucleotide position was generated using SAMtools on the primer trimmed alignment files.



# Figure 5. Identification of SNPs responsible for low coverage of amplicons 15 and 75 in BA.2 samples.

Multiple sequence alignment using MAFFT (v7.505) of NC\_045512.2 reference with selected BA.2 samples with A.

reduced coverage of amplicon 15 or B. reduced coverage of amplicon 75. Alignments viewed using Jalview

(v2.11.2.2).



**Figure S1. Sequencing coverage and aln2type VOC-21NOV-01 defining mutations.** Analysis of 106 BA.1 samples with V4.1 primers. **A.** Sequencing depth of variant defining mutations at all 17 nucleotide positions as defined by aln2type for BA.1. **B.** Number of samples with masked bases (N's) at variant defining nucleotide positions in BA.1 samples.



**Figure S2. Sequencing coverage and aln2type VUI-22JAN-01 defining mutations.** Analysis of 168 BA.2 samples. **A.** Sequencing depth of variant defining mutations at all 20 nucleotide positions as defined by aln2type for BA.2. **B.** Number of samples with masked bases (N's) at variant defining nucleotide positions in BA.2 samples.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.01.22282842; this version posted December 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Berpetuity. It is made available under a CC-BY 4.0 International license . A29510C **★♦** 29513 29493 29503 29533 29523 NC 045512.2 CCAAACAATTGCAACAATCCATGAGCAGTGCTGACTCAACTCAGGCCTAAACTCA vssfru 297 CCAAACAATTGCAACAATCCATGAGCCTTGCTGACTCAACTCAGGCCTAAACTCA vssfru\_298 CCAAACAATTGCAACAATCCATGAGCCTTGCTGACTCAACTCAGGCCTAAACTCA vssfru 299 CCAAACAATTGCAACAATCCATGAGCCTTGCTGACTCAACTCAGGCCTAAACTCA vssfru\_300 CCAAACAATTGCAACAATCCATGAGCCTTGCTGACTCAACTCAGGCCTAAACTCA vssfru\_301 CCAAACAATTGCAACAATCCATGAGCCTTGCTGACTCAACTCAGGCCTAAACTCA vssfru 302 CCAAACAATTGCAACAATCCATGAGCCTTGCTGACTCAACTCAGGCCTAAACTCA vssfru\_303 CCAAACAATTGCAACAATCCATGAGCCTTGCTGACTCAACTCAGGCCTAAACTCA vssfru\_304 CCAAACAATTGCAACAATCCATGAGCCTTGCTGACTCAACTCAGGCCTAAACTCA vssfru 305 CCAAACAATTGCAACAATCCATGAGCCTTGCTGACTCAACTCAGGCCTAAACTCA

vssfru\_306 CCAAACAATTGCAACAATCCATGAGCCTTGCTGACTCAACTCAGGCCTAAACTCA vssfru\_253 CCAAACAATTGCAACAATCCATGAGCCGTGCTGACTCAACTCAGGCCTAAACTCA

3'

GCTGACTCAACTCAGGCCTAAA SARS-CoV-2\_98\_RIGHT primer (reverse complement)

# Figure S3. A29510C aln2type mixed-call status due to downstream mutation present in subset of samples.

Multiple sequence alignment using MAFFT (v7.505) of NC 045512.2 reference with 10 BA.2 samples with mixed-

call status for A29510C variant defining mutation and vssfru 253 (A29510C detected). Alignment viewed using

Jalview (v2.11.2.2).